Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Avon Technologies PLC (AVON.L)
GBp1,654.00
-4.00 (-0.24%)
GB LSE Healthcare Medical - Specialties
Address
Hampton Park West SN12 6NB
Melksham, GB
Melksham, GB
CEO
Mark Josceline Sclater
Website
avon-technologiesplc.com
IPO
1988-07-01
ISIN GB0000667013
Also trades on
London Stock Exchange · AVON.L (GBp)
Other OTC · AVNBF (USD)
Description
Avon Technologies Plc specializes in the development and production of respiratory protection equipment, catering to both military and industrial clients. The company further supplies polymer-based products to the dairy and defense sectors. Operating through its Respiratory Protection and Head Protection divisions, this firm, founded in 1885, is based in Melksham, United Kingdom.
News Sentiment (7d)
Based on only 1 article — low confidence
- Gold traders bet on rebound stalling near $4,300 after sharp first-half slump Proactive Investors - Finance
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
GBp1,654.00
-4.00 (-0.24%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
93.4K
Beta
0.23
Float Shares
28.52M
Free Float %
96.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +4.53% | -2.42% | -10.63% | -7.13% | -14.78% | -11.03% | +3.99% | +67.60% | -46.98% | +81.35% | +224.10% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
1,654.00
DCF (Unlevered)
1,112.06
-32.8%
DCF (Levered)
1,715.55
+3.7%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
50% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 4 | +1 |
| Hold | 4 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
5.18
Safe zone
Piotroski F-Score
8 / 9
Strong
MOAT Score
2 / 10
No MOAT
Composite Rating
B+
Overall Score
3 / 5
Medium
DCF Score
4 / 5
High
ROE Score
4 / 5
High
ROA Score
4 / 5
High
D/E Score
2 / 5
Medium
P/E Score
2 / 5
Medium
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Specialties: +8.3%-12.6% Q1'26: +56.3% (vs Q1'24)
-
EPS growth Medical - Specialties: +10.1%+168.0% ★ Q1'26: +1,230.1% (vs Q1'24)
-
FCF margin FCF growth · Medical - Specialties: +51.3%+3.6% Q1'26: -0.2% (vs Q1'24)
-
EBIT margin Medical - Specialties: +12.6%+6.1% Q1'26: +13.4% (vs Q1'24)
-
ROIC Medical - Specialties: +6.6%+4.9% Q1'26: +25.8% (vs Q1'24)
-
Share dilution Medical - Specialties: 0.0%-0.8% ★ Q1'26: +2.3% (vs Q1'24)
-
Debt / EBITDA Net debt/EBITDA · Medical - Specialties: -0.39×2.67× Q1'26: 0.72× (vs Q1'24)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Sep 2009 actual |
Sep 2010 actual |
Sep 2011 actual |
Sep 2012 actual |
Sep 2013 actual |
Sep 2014 actual |
Sep 2015 actual |
Sep 2016 actual |
Sep 2017 actual |
Sep 2018 actual |
Sep 2019 actual |
Sep 2020 actual |
Sep 2021 actual |
Sep 2022 actual |
Sep 2023 actual |
Sep 2024 actual |
Sep 2025 actual |
Sep 2026 6 Rev. Ana. 5 EPS Ana. |
Sep 2027 6 Rev. Ana. 5 EPS Ana. |
Sep 2028 6 Rev. Ana. 4 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
161.47M
est: 88.56M (+82.3%)
|
185.72M
est: 116.76M (+59.1%)
|
167.80M
est: 109.60M (+53.1%)
|
172.11M
est: 109.95M (+56.5%)
|
201.83M
est: 127.26M (+58.6%)
|
202.65M
est: 128.40M (+57.8%)
|
203.55M
est: 136.46M (+49.2%)
|
142.90M
est: 141.84M (+0.7%)
|
159.20M
est: 163.01M (-2.3%)
|
165.50M
est: 163.04M (+1.5%)
|
128.40M
est: 180.58M (-28.9%)
|
168.00M
est: 205.53M (-18.3%)
|
245.15M
est: 185.57M (+32.1%)
|
228.58M
est: 247.76M (-7.7%)
|
243.80M
est: 269.30M (-9.5%)
|
275.00M
est: 203.68M (+35.0%)
|
240.43M
est: 228.69M (+5.1%)
|
253.56M
252.36M – 255.77M
+10.9% YoY
|
270.74M
265.56M – 279.12M
+6.8% YoY
|
289.56M
286.04M – 295.40M
+7.0% YoY
|
| EBITDA |
12.09M
est: -15.31M (+178.9%)
|
19.67M
est: 5.22M (+276.7%)
|
23.92M
est: 9.41M (+154.3%)
|
25.81M
est: 13.93M (+85.2%)
|
30.72M
est: 17.51M (+75.4%)
|
32.99M
est: 18.99M (+73.7%)
|
39.59M
est: 20.76M (+90.7%)
|
30.00M
est: 26.44M (+13.5%)
|
31.80M
est: 32.21M (-1.3%)
|
33.00M
est: 30.85M (+7.0%)
|
25.24M
est: 37.10M (-32.0%)
|
23.00M
est: 33.11M (-30.5%)
|
-2.27M
est: 39.07M (-105.8%)
|
24.70M
est: 40.26M (-38.7%)
|
8.00M
est: 19.97M (-59.9%)
|
30.90M
est: 15.15M (+104.0%)
|
30.48M
est: 16.96M (+79.8%)
|
18.80M
18.71M – 18.97M
+10.9% YoY
|
20.08M
19.69M – 20.70M
+6.8% YoY
|
21.47M
21.21M – 21.91M
+7.0% YoY
|
| EBIT |
5.44M
est: -18.95M (+128.7%)
|
14.64M
est: 2.77M (+428.9%)
|
16.76M
est: 8.73M (+92.0%)
|
40.12M
est: 11.14M (+260.3%)
|
20.67M
est: 13.43M (+53.9%)
|
22.98M
est: 13.52M (+70.0%)
|
28.31M
est: 15.10M (+87.5%)
|
21.89M
est: 20.05M (+9.2%)
|
19.20M
est: 19.12M (+0.4%)
|
21.90M
est: 19.01M (+15.2%)
|
12.54M
est: 23.54M (-46.7%)
|
2.70M
est: 18.70M (-85.6%)
|
-29.60M
est: 22.06M (-234.2%)
|
7.61M
est: 22.73M (-66.5%)
|
-12.80M
est: -899.0K (-1,323.9%)
|
10.70M
est: -681.9K (+1,669.1%)
|
14.55M
est: -763.4K (+2,006.3%)
|
-846.4K
-853.8K – -842.4K
-10.9% YoY
|
-903.8K
-931.7K – -886.5K
-6.8% YoY
|
-966.6K
-986.1K – -954.8K
-7.0% YoY
|
| Net Income |
-292.9K
est: -29.33M (+99.0%)
|
6.83M
est: -263.7K (+2,691.4%)
|
11.10M
est: 4.04M (+175.0%)
|
12.64M
est: 7.12M (+77.4%)
|
15.56M
est: 9.03M (+72.4%)
|
17.56M
est: 9.69M (+81.3%)
|
20.71M
est: 11.41M (+81.6%)
|
17.60M
est: 15.03M (+17.1%)
|
21.50M
est: 20.57M (+4.5%)
|
20.30M
est: 21.39M (-5.1%)
|
17.58M
est: 23.22M (-24.3%)
|
7.00M
est: 18.57M (-62.3%)
|
-25.28M
est: 21.91M (-215.4%)
|
-6.59M
est: 22.58M (-129.2%)
|
-14.40M
est: -17.80M (+19.1%)
|
3.00M
est: 6.50M (-53.8%)
|
7.89M
est: 18.78M (-58.0%)
|
27.97M
26.98M – 28.97M
+49.0% YoY
|
32.35M
29.55M – 33.62M
+15.6% YoY
|
37.30M
32.07M – 39.22M
+15.3% YoY
|
| SGA |
22.52M
est: 18.05M (+24.7%)
|
16.13M
est: 28.48M (-43.3%)
|
14.27M
est: 17.93M (-20.4%)
|
31.01M
est: 18.66M (+66.2%)
|
32.80M
est: 22.22M (+47.6%)
|
44.16M
est: 20.48M (+115.6%)
|
40.63M
est: 25.87M (+57.1%)
|
41.44M
est: 28.27M (+46.6%)
|
47.56M
est: 34.85M (+36.5%)
|
49.90M
est: 35.32M (+41.3%)
|
26.60M
est: 41.55M (-36.0%)
|
74.60M
est: 53.50M (+39.4%)
|
36.63M
est: 63.13M (-42.0%)
|
46.15M
est: 65.05M (-29.1%)
|
88.30M
est: 70.73M (+24.8%)
|
81.00M
est: 53.65M (+51.0%)
|
73.38M
est: 60.06M (+22.2%)
|
66.60M
66.28M – 67.18M
+10.9% YoY
|
71.11M
69.75M – 73.31M
+6.8% YoY
|
76.05M
75.13M – 77.59M
+7.0% YoY
|
| EPS |
-0.01
est: 0.08 (-112.4%)
|
0.24
est: 0.16 (+53.6%)
|
0.39
est: 0.25 (+54.6%)
|
0.43
est: 0.26 (+65.3%)
|
0.53
est: 0.33 (+62.2%)
|
0.59
est: 0.41 (+43.6%)
|
0.69
est: 0.51 (+34.7%)
|
0.58
est: 0.65 (-10.8%)
|
0.71
est: 0.65 (+9.4%)
|
0.67
est: 0.74 (-9.7%)
|
0.46
est: 0.86 (-46.8%)
|
0.23
est: 0.90 (-74.3%)
|
-0.82
est: 0.49 (-266.0%)
|
-0.22
est: 0.05 (-581.4%)
|
-0.48
est: -0.59 (+19.1%)
|
0.10
est: 0.49 (-79.4%)
|
0.27
est: 0.62 (-56.3%)
|
0.91
0.88 – 0.95
+47.5% YoY
|
1.02
0.96 – 1.10
+12.2% YoY
|
1.14
1.05 – 1.28
+11.9% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-14 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-13 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-12 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-11 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-08 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-07 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-06 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-05 | B- | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-01 | B- | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-30 | B- | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-29 | B- | 2/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-28 | B- | 2/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-27 | B- | 2/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-24 | B- | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-23 | B- | 2/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | B- | 2/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | B- | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | B- | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | B- | 3/5 | 4/5 | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | B- | 3/5 | 4/5 | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
79.87M
OE per share TTM
2.56
Owner's Yield
16.83%
Maintenance CapEx ratio
80.98%
Maint CapEx / Avg PPE
19.4%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 44 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | abrdn International Small Cap Active ETF ASCI | 0.82% | 645.9K | 1.05% |
| 2 | WisdomTree Europe Defense Fund WDEF | 0.30% | 274.6K | 0.45% |
| 3 | Amundi Prime UK Mid & Small Cap UCITS ETF DR - GBP (D) PRUK.L | 0.29% | 1.25M | 0.05% |
| 4 | Xtrackers FTSE 250 UCITS ETF 1D XMCX.L | 0.17% | 66.1K | 0.15% |
| 5 | Vanguard FTSE 250 UCITS ETF VMIG.MI | 0.17% | 4.44M | 0.10% |
| 6 | Vanguard FTSE 250 UCITS ETF (GBP) Distributing VMID.DE | 0.17% | 4.44M | 0.10% |
| 7 | HSBC FTSE 250 UCITS ETF HMCX.L | 0.17% | 112.0K | 0.09% |
| 8 | Invesco FTSE 250 UCITS ETF S250.L | 0.16% | 56.2K | 0.12% |
| 9 | iShares FTSE 250 UCITS ETF MIDD.L | 0.16% | 1.33M | 0.40% |
| 10 | WisdomTree Europe Defence UCITS ETF - EUR Acc WDEF.L | 0.14% | 6.82M | 0.40% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
15.9K
Shares Outstanding
29.70M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Mark Josceline Sclater | Chief Executive Officer & Director | 1M | male |
| Richard John Cashin | Chief Financial Officer & Executive Director | 922.0K | male |
| James Wilcox | President of Team Wendy | — | male |
| Kate Vizmeg | Group HR Director | — | female |
| Kent Moeller | President of Avon Protection Ceradyne | — | — |
| Steve Elwell | President of Avon Protection | — | male |
| Chandlar Gabara | Continuous Improvement Leader | — | male |
| Zoe Elizabeth Holland | General Counsel & Company Secretary | — | female |
| Gary Dunn | Vice President of Sales & Marketing | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for AVON.L
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
